Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Chronic myelomonocytic leukemia

Chronic myelomonocytic leukemia

Part of Leukemia

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Chronic myelomonocytic leukemia

61 trials tracked for Chronic myelomonocytic leukemia: 5 in phase 3 or 4 and 2 with published results. The most-cited published study has 122 citations.

61Trials tracked
5Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 5 Phase 2 43 Phase 1 6 Other / NA 7
  1. Phase 3 Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) Completed · 122 cited
  2. Phase 3 Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML Completed · 88 cited
  3. Phase 3 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed
  4. Phase 3 Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Completed
  5. Phase 3 Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML Completed
  6. Phase 2 Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation Completed
Show 44 more trials
  1. Phase 2 Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Completed
  2. Phase 2 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Completed
  3. Phase 2 Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia Completed
  4. Phase 2 Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Completed
  5. Phase 2 An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) Completed
  6. Phase 2 Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS Completed
  7. Phase 2 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  8. Phase 2 Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia Completed
  9. Phase 2 Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Completed
  10. Phase 2 A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). Completed
  11. Phase 2 Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms Completed
  12. Phase 2 Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed
  13. Phase 2 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed
  14. Phase 2 Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies Completed
  15. Phase 2 MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia Completed
  16. Phase 2 Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant Completed
  17. Phase 2 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia Completed
  18. Phase 2 Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome Completed
  19. Phase 2 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed
  20. Phase 2 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed
  21. Phase 2 Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Completed
  22. Phase 2 Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Completed
  23. Phase 2 Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant Completed
  24. Phase 2 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed
  25. Phase 2 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  26. Phase 2 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Completed
  27. Phase 2 Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm Completed
  28. Phase 2 Oral Clofarabine Study in Patients With Myelodysplastic Syndrome Completed
  29. Phase 2 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies Completed
  30. Phase 2 Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia Completed
  31. Phase 2 Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) Completed
  32. Phase 2 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed
  33. Phase 2 Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Completed
  34. Phase 2 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed
  35. Phase 2 WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed
  36. Phase 2 Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders Completed
  37. Phase 2 Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Completed
  38. Phase 2 Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  39. Phase 2 Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome Completed
  40. Phase 2 A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia Completed
  41. Phase 2 Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) Completed
  42. Phase 2 Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) Completed
  43. Phase 1 Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS Completed
  44. Phase 1 A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients Completed

Showing the 50 most-cited and recently-updated of 61 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Chronic myelomonocytic leukemia: what the trials found

Fludarabine has been evaluated in multiple clinical trials for the treatment of chronic myelomonocytic leukemia (CMML) [1, 10, 20]. In one study involving a cohort with varying tacrolimus prophylaxis durations, 33% to 42% of participants were able to discontinue prophylactic tacrolimus, with only one instance of Grade III-IV acute GVHD reported in the 90-day cohort 20.

Azacitidine has been investigated across several trials for CMML [12, 14, 19]. In a large Phase 3 trial (N=454), Azacitidine did not show statistically significant differences in Event-Free Survival (p=0.557), Overall Survival (p=0.152), or Time to AML Transformation (p=0.562) compared to the control group 3.

Guadecitabine was evaluated in a Phase 3 trial (N=417); while it did not show statistically significant differences in Overall Survival (p=0.6063), results were reported for transfusion independence and marrow complete response rates 6. Other established interventions include Glasdegib 5 and ASTX727, the latter of which was evaluated regarding LINE-1 demethylation percentages and Grade 3 or higher treatment-emergent adverse events in MDS/CMML patients 4.

A supersaturated calcium phosphate rinse was shown to maintain a consistent duration of severe oral mucositis (WHO Grade 3 or 4) at 4.5 for the study population 7.

Recent results — preliminary, needs further review

  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401 was evaluated in a Phase 1 trial (N=8) 2.
  • Fludarabine phosphate was investigated in a Phase 2 trial (N=62) 9.
  • Donor Lymphocytes were evaluated in a Phase 2 trial (N=55) 8.

For the clinician treating this condition

  • Fludarabine is established as an intervention for CMML, with data available regarding its use alongside tacrolimus prophylaxis [1, 10, 20].
  • Azacitidine has been tested in large-scale trials; however, significant improvements in EFS, OS, or time to AML transformation were not observed in the primary Phase 3 study reported [3, 12, 14, 19].
  • Guadecitabine showed no statistically significant difference in Overall Survival compared to control groups in a large trial 6.

AI synthesis of 9 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report and review: azacytidine plus ruxolitinib in connective tissue disease with CMML and myelofibrosis
Allergy & Immunology Sys. Review
Case report and review: azacytidine plus ruxolitinib in connective tissue disease with CMML and myelofibrosis A single patient found relief from blood cancer with a new drug combo
This case report and literature review describes a 52-year-old male with connective tissue disease, chronic myelomonocytic leukemia, and mye…
One man with blood cancer saw his fever and anemia improve after two years on a specific drug mix, offering a glimpse into potential new tre…
Frontiers May 14, 2026
Decitabine versus hydroxyurea in advanced chronic myelomonocytic leukemia shows survival differences linked to baseline counts
Oncology RCT
Decitabine versus hydroxyurea in advanced chronic myelomonocytic leukemia shows survival differences linked to baseline counts Keeping Blood Cell Counts Low in Leukemia Predicts Who Lives Longer
This randomized controlled trial (RCT) enrolled 120 patients with advanced proliferative chronic myelomonocytic leukemia (CMML) comparing de…
In chronic myelomonacytic leukemia, keeping abnormal blood cells low after treatment predicts who lives longer than bone marrow changes alon…
Apr 18, 2026
Case report: CMML initially diagnosed as ITP in one patient, stabilized with decitabine
Hematology
Case report: CMML initially diagnosed as ITP in one patient, stabilized with decitabine A single case shows leukemia can initially look like a different blood disorder
A case report describes one patient initially diagnosed with immune thrombocytopenia (ITP) who was later found to have chronic myelomonocyti…
A single case shows leukemia can initially look like a different blood disorder, so doctors must watch for hidden mutations when standard tr…
Frontiers Apr 1, 2026

Research across Leukemia

Related studies from across the Leukemia family.

TKI plus chemotherapy achieves deep molecular remission in Ph+ leukemia case with diagnostic framework
Allergy & Immunology Meta-analysis
TKI plus chemotherapy achieves deep molecular remission in Ph+ leukemia case with diagnostic framework One patient's leukemia remission offers clues for rare diagnosis
This systematic review with a case report describes a patient with Philadelphia chromosome-positive leukemia who achieved complete remission…
A patient with a rare leukemia achieved deep remission for 35 months. The case highlights how to tell apart two similar-looking blood cancer…
Frontiers Jul 29, 2026
Imatinib achieves complete cytogenetic response in a pediatric patient with suspected chronic myeloid leukemia
Pediatrics Sys. Review
Imatinib achieves complete cytogenetic response in a pediatric patient with suspected chronic myeloid leukemia Imatinib works for CML in child with high platelets
This case report describes a pediatric patient with isolated thrombocytosis who achieved a complete cytogenetic response to imatinib after f…
A child with high platelets and no response to standard therapy was found to have CML and responded to imatinib.
Frontiers Jul 21, 2026
Venetoclax plus intensive chemo yields 63.79% ORR in relapsed/refractory AML meta-analysis
Hematology Meta-analysis
Venetoclax plus intensive chemo yields 63.79% ORR in relapsed/refractory AML meta-analysis Venetoclax combo shows promise for hard-to-treat leukemia
A meta-analysis of 235 patients with relapsed/refractory AML found that venetoclax combined with intensive chemotherapy achieved a pooled ov…
For patients with relapsed AML, venetoclax plus intensive chemo led to a 64% response rate in a new analysis.
Jul 1, 2026
GSTO1 inhibition induces apoptosis in AML cells while LMRS model stratifies patient risk
Allergy & Immunology Guideline
GSTO1 inhibition induces apoptosis in AML cells while LMRS model stratifies patient risk New lipid metabolism markers help predict outcomes for leukemia patients
This guideline synthesizes in vitro and observational data regarding lipid metabolism in acute myeloid leukemia (AML). The findings identify…
Researchers identified a new way to group and predict survival for patients with acute myeloid leukemia using lipid metabolism patterns.
Frontiers Jun 30, 2026
Asparaginase therapy in acute lymphoblastic leukemia patients correlates with increased thromboembolism risk in specific subgroups
Oncology Meta-analysis
Asparaginase therapy in acute lymphoblastic leukemia patients correlates with increased thromboembolism risk in specific subgroups Adults with Leukemia Show Higher Risk of Blood Clots
This meta-analysis examined the incidence of thromboembolism among patients with acute lymphoblastic leukemia receiving asparaginase based c…
Patients with acute lymphoblastic leukemia treated with asparaginase face higher risks of blood clots, especially adults and those with spec…
Jun 26, 2026
Low-dose ATG plus PTCy shows no significant difference in acute GVHD compared to standard regimens
Hematology RCT
Low-dose ATG plus PTCy shows no significant difference in acute GVHD compared to standard regimens Trial Shows New Treatment Strategy for Leukemia Stem Cell Transplant
This randomized trial of 407 patients with AML or MDS undergoing haploidentical transplant found that low-dose ATG plus PTCy did not signifi…
A new combination of medications may help patients recover blood cells faster after a stem cell transplant for leukemia or blood disorders.
Blood Jun 25, 2026
Venetoclax-based combinations show superior progression-free survival compared to chemoimmunotherapy in CLL without TP53 aberrations
Oncology RCT
Venetoclax-based combinations show superior progression-free survival compared to chemoimmunotherapy in CLL without TP53 aberrations Trial shows venetoclax combinations improve progression-free survival in CLL
This Phase 3 randomized controlled trial of 926 patients with CLL without TP53 aberrations found that venetoclax-based regimens (RV, GV, and…
New clinical trial results show that specific venetoclax combinations can keep chronic lymphocytic leukemia stable for longer than standard …
Blood Jun 20, 2026
AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life
Oncology Meta-analysis
AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life New combinations show promise for older adults with myeloid leukemia
This systematic review and meta-analysis of 47 studies evaluated treatments for older adults with AML ineligible for conventional chemothera…
Combining specific drugs like venetoclax with other treatments may improve survival and quality of life for older adults with acute myeloid …
Jun 12, 2026
7-day venetoclax with intensive chemotherapy achieves 90.3% composite complete remission in AML
Hematology RCT
7-day venetoclax with intensive chemotherapy achieves 90.3% composite complete remission in AML Trial shows venetoclax combined with chemotherapy for AML
This clinical trial of 259 newly diagnosed patients with acute myeloid leukemia found a 90.3% composite complete remission rate using a 7-da…
A new clinical trial shows that a short 7-day course of venetoclax combined with chemotherapy can achieve high remission rates in AML patien…
Jun 8, 2026
Rate of drug concentration rise alters hemodynamic responses and mortality risk in coronary heart disease patients
Drug Pipeline Meta-analysis
Rate of drug concentration rise alters hemodynamic responses and mortality risk in coronary heart disease patients New analysis shows how fast drug levels change affects patient safety outcomes
This narrative review and theoretical framework synthesizes evidence on rate-dependent pharmacology. It highlights divergent hemodynamic res…
This review explains that how quickly medicine levels rise in the body matters for safety. Fast changes can cause more harm than slow ones, …
medRxiv Jun 4, 2026
Novel strategies aim to separate GVHD from GVL effects in allo-HCT for AML
Oncology Sys. Review
Novel strategies aim to separate GVHD from GVL effects in allo-HCT for AML Novel strategies aim to separate GVHD from GVL effects in leukemia patients
This narrative review explores novel therapeutic strategies to separate graft-versus-host disease (GVHD) from graft-versus-leukemia (GVL) ef…
A narrative review explores new ways to treat acute myeloid leukemia while managing side effects after stem cell transplants.
Frontiers Jun 4, 2026
HMA-venetoclax yields 50% overall response rate in relapsed/refractory AML meta-analysis
Hematology Meta-analysis
HMA-venetoclax yields 50% overall response rate in relapsed/refractory AML meta-analysis Combination therapy shows response in relapsed leukemia
This systematic review and meta-analysis of 2289 adults with relapsed/refractory acute myeloid leukemia found that hypomethylating agents pl…
For adults with relapsed leukemia, combining two drugs led to a 50% response rate, offering a potential new option for a tough situation.
Jun 1, 2026

Questions about Chronic myelomonocytic leukemia

Can ruxolitinib help CMML patients who also have connective tissue disease?

A specific case report shows that combining azacytidine with ruxolitinib helped a patient with connective tissue disease, CMML, and myelofibrosis by reducing fever, correcting high monocyte counts, and improving anemia.

Full answer →
What happens if a CMML patient is first diagnosed with ITP?

CMML can be misdiagnosed as ITP when thrombocytopenia is the first symptom; immunosuppressive therapy may temporarily raise platelets, but the underlying CMML progresses. Decitabine can stabilize the condition.

Full answer →